Show simple item record

dc.contributor.authorSabater, L.en_US
dc.contributor.authorTitulaer, M.en_US
dc.contributor.authorSaiz, A.en_US
dc.contributor.authorVerschuuren, J.en_US
dc.contributor.authorGüre, A. O.en_US
dc.contributor.authorGraus, F.en_US
dc.date.accessioned2016-02-08T10:10:02Z
dc.date.available2016-02-08T10:10:02Z
dc.date.issued2008en_US
dc.identifier.issn0028-3878
dc.identifier.urihttp://hdl.handle.net/11693/23183
dc.description.abstractBACKGROUND/OBJECTIVE: We reported that 43% of patients with Lambert-Eaton myasthenic syndrome (LEMS) and small cell lung cancer (SCLC) had an antibody called anti-glial nuclear antibody (AGNA), defined by the immunoreaction with the nuclei of the Bergmann glia of the cerebellum. This study was undertaken to identify the antigen recognized by AGNA and to confirm the association with paraneoplastic LEMS in a larger series. METHODS: We probed a fetal brain cDNA library with AGNA-positive sera. The presence of antibodies against the isolated antigen was detected by immunoblot of phage plaques from two positive clones. We studied 105 patients with LEMS (55 with SCLC), 50 with paraneoplastic neurologic syndromes, SCLC, and Hu antibodies, and 50 with only SCLC. RESULTS: Probing of the fetal brain expression library with AGNA sera resulted in the isolation of SOX1, a highly immunogenic tumor antigen in SCLC. IgG eluted from SOX1 clones produced the same cerebellar immunoreactivity as of AGNA sera. SOX1 antibodies were present in 64% of patients with LEMS and SCLC but in none of the 50 with idiopathic LEMS (p < 0.0001). Compared with paraneoplastic LEMS, the frequency of SOX1 antibodies was significantly lower in patients with Hu antibodies (32%, p = 0.002) and in those with only SCLC (22%). CONCLUSIONS: SOX1 is the antigen recognized by anti-glial nuclear antibody-positive sera. The detection of SOX1 antibodies in patients with Lambert-Eaton myasthenic syndrome (LEMS) predicts the presence of small cell lung cancer and may be used to follow more closely those LEMS patients with no evidence of cancer at the initial workup.en_US
dc.language.isoEnglishen_US
dc.source.titleNeurologyen_US
dc.relation.isversionofhttp://dx.doi.org/10.1212/01.wnl.0000281663.81079.24en_US
dc.subjectAntinuclear antibodyen_US
dc.subjectGlial nuclear antibodyen_US
dc.subjectHu antibodyen_US
dc.subjectTranscription factor Sox1en_US
dc.subjectTumor antigenen_US
dc.subjectUnclassified drugen_US
dc.subjectAntigen detectionen_US
dc.subjectArticleen_US
dc.subjectControlled studyen_US
dc.subjectDNA libraryen_US
dc.subjectEaton lambert syndromeen_US
dc.subjectFemaleen_US
dc.subjectGene deletionen_US
dc.subjectHumanen_US
dc.subjectHuman tissueen_US
dc.subjectImmunoblottingen_US
dc.subjectImmunoreactivityen_US
dc.subjectLung small cell canceren_US
dc.subjectMajor clinical studyen_US
dc.subjectNucleotide sequenceen_US
dc.subjectPriority journalen_US
dc.subjectAgeden_US
dc.subjectAnimalsen_US
dc.subjectAntigens, Neoplasmen_US
dc.subjectAutoantibodiesen_US
dc.subjectBiological markersen_US
dc.subjectCalcium channelsen_US
dc.subjectCarcinoma, small cellen_US
dc.subjectCerebellumen_US
dc.subjectDNA-Binding Proteinsen_US
dc.subjectFemaleen_US
dc.subjectHigh Mobility Group Proteinsen_US
dc.subjectHumansen_US
dc.subjectImmunoblottingen_US
dc.subjectLambert-Eaton myasthenic syndromeen_US
dc.subjectLung neoplasmsen_US
dc.subjectMaleen_US
dc.subjectNeurogliaen_US
dc.subjectParaneoplastic syndromesen_US
dc.subjectPredictive value of testsen_US
dc.subjectPrognosisen_US
dc.subjectRatsen_US
dc.subjectTumor markers, biologicalen_US
dc.titleSOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndromeen_US
dc.typeArticleen_US
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.citation.spage924en_US
dc.citation.epage928en_US
dc.citation.volumeNumber70en_US
dc.citation.issueNumber12en_US
dc.identifier.doi10.1212/01.wnl.0000281663.81079.24en_US
dc.publisherLippincott Williams & Wilkinsen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record